{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:15:04Z","timestamp":1779902104198,"version":"3.53.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82160146"],"award-info":[{"award-number":["No. 82160146"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital","award":["Grant numbers CY2021-MS-A12"],"award-info":[{"award-number":["Grant numbers CY2021-MS-A12"]}]},{"name":"Investigation of the Effects and Mechanisms of HTRA1 on Bladder Tumors Through Combined Non-invasive Urinary Metabolomics","award":["Grant numbers 22YF7FA090"],"award-info":[{"award-number":["Grant numbers 22YF7FA090"]}]},{"name":"Research Based on Novel Optical Fiber Biosensors for Multi-Parameter High-Sensitivity Real-Time Detection of Bladder Cancer Urinary Biomarkers","award":["Grant numbers 24YFFA049"],"award-info":[{"award-number":["Grant numbers 24YFFA049"]}]},{"name":"The Special Fund Project for Central Guiding Local Science and Technology Development","award":["Grant numbers 24ZYQA050"],"award-info":[{"award-number":["Grant numbers 24ZYQA050"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Bladder cancer (BLCA) represents one of the most prevalent urological malignancies worldwide. Bridging integrator 1 (BIN1), a well-characterized tumor suppressor that interacts with and inhibits oncogenic Myc transcription factors, has demonstrated crucial roles in various cancer types. However, its specific functions and underlying molecular mechanisms in BLCA development and progression remain poorly understood. This study aims to elucidate the role of BIN1 in regulating BLCA cell proliferation, metastasis, and cancer stem cell properties.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Using urinary proteomics analysis, we identified BIN1 as a significantly dysregulated protein in BLCA. The clinical significance of BIN1 was further validated through comprehensive analyses of public databases. BIN1 expression levels defined distinct molecular and immunological subtypes of BLCA. Through proteomic profiling of BIN1-overexpressing UMUC3 cells and corresponding controls, we identified ALDH1 as a key downstream effector in the BIN1-regulated ALDH1\/NOTCH signaling axis. We employed multiple experimental approaches, including Western blot analysis, quantitative RT-PCR, immunofluorescence staining, wound healing assays, transwell migration assays, colony formation assays, tumor sphere formation assays, flow cytometry, CCK8 proliferation assays, and cell transfection experiments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We observed significant downregulation of BIN1 in both BLCA tissues and cell lines compared to normal adjacent tissues and SV-HUC-1 cells, respectively. BIN1 overexpression inhibited cancer cell proliferation by promoting apoptosis and suppressed epithelial-mesenchymal transition (EMT), thereby reducing local invasion and distant metastasis. Additionally, BIN1 regulated cancer stem cell properties through modulation of ALDH1 expression, with NOTCH2 acting as a crucial downstream mediator of ALDH1 signaling.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our findings demonstrate that BIN1 functions as a tumor suppressor in BLCA and suggest its potential utility as both a diagnostic biomarker and therapeutic target for BLCA treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41065-025-00384-w","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:37:07Z","timestamp":1740746227000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["BIN1 inhibited tumor growth, metastasis and stemness by ALDH1\/NOTCH pathway in bladder carcinoma"],"prefix":"10.1186","volume":"162","author":[{"given":"Si-yu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-long","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-ran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-long","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-peng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-jun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-yun","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan-jie","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"8","key":"384_CR1","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","volume":"38","author":"A Richters","year":"2020","unstructured":"Richters A, Aben KKH, Kiemeney L. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38(8):1895\u2013904.","journal-title":"World J Urol"},{"issue":"4","key":"384_CR2","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/stem.1625","volume":"32","author":"GM Dancik","year":"2014","unstructured":"Dancik GM, Owens CR, Iczkowski KA, Theodorescu D. A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors. Stem Cells. 2014;32(4):974\u201382.","journal-title":"Stem Cells"},{"key":"384_CR3","doi-asserted-by":"crossref","unstructured":"Matuszczak M, Salagierski M. Diagnostic and prognostic potential of biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in bladder cancers. Int J Mol Sci 2020, 21(9).","DOI":"10.3390\/ijms21093360"},{"issue":"3","key":"384_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.urolonc.2021.10.010","volume":"40","author":"LS Mertens","year":"2022","unstructured":"Mertens LS, Claps F, Mayr R, Bostrom PJ, Shariat SF, Zwarthoff EC, et al. Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. Urol Oncol. 2022;40(3):110. e111-110 e119.","journal-title":"Urol Oncol"},{"issue":"1","key":"384_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R, Comperat EM, Cowan NC, Gakis G, et al. European Association of Urology Guidelines on muscle-invasive and metastatic bladder Cancer: Summary of the 2020 guidelines. Eur Urol. 2021;79(1):82\u2013104.","journal-title":"Eur Urol"},{"issue":"1","key":"384_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"384_CR7","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","volume":"71","author":"J Alfred Witjes","year":"2017","unstructured":"Alfred Witjes J, Lebret T, Comp\u00e9rat EM, Cowan NC, De Santis M, Bruins HM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder Cancer. Eur Urol. 2017;71(3):462\u201375.","journal-title":"Eur Urol"},{"issue":"6","key":"384_CR8","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.cell.2006.03.011","volume":"124","author":"MF Clarke","year":"2006","unstructured":"Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell. 2006;124(6):1111\u20135.","journal-title":"Cell"},{"issue":"10","key":"384_CR9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrc2499","volume":"8","author":"JE Visvader","year":"2008","unstructured":"Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8(10):755\u201368.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"384_CR10","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/1096-911X(20001201)35:6<559::AID-MPO14>3.0.CO;2-J","volume":"35","author":"MD Hogarty","year":"2000","unstructured":"Hogarty MD, Liu X, Thompson PM, White PS, Sulman EP, Maris JM, et al. BIN1 inhibits colony formation and induces apoptosis in neuroblastoma cell lines with MYCN amplification. Med Pediatr Oncol. 2000;35(6):559\u201362.","journal-title":"Med Pediatr Oncol"},{"issue":"15","key":"384_CR11","first-page":"3258","volume":"57","author":"R Wechsler-Reya","year":"1997","unstructured":"Wechsler-Reya R, Elliott K, Herlyn M, Prendergast GC. The putative tumor suppressor BIN1 is a short-lived nuclear phosphoprotein, the localization of which is altered in malignant cells. Cancer Res. 1997;57(15):3258\u201363.","journal-title":"Cancer Res"},{"issue":"1","key":"384_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1006\/geno.1998.5709","volume":"56","author":"NC Mao","year":"1999","unstructured":"Mao NC, Steingrimsson E, DuHadaway J, Wasserman W, Ruiz JC, Copeland NG, et al. The murine Bin1 gene functions early in myogenesis and defines a new region of synteny between mouse chromosome 18 and human chromosome 2. Genomics. 1999;56(1):51\u20138.","journal-title":"Genomics"},{"issue":"7","key":"384_CR13","first-page":"3151","volume":"61","author":"JB DuHadaway","year":"2001","unstructured":"DuHadaway JB, Sakamuro D, Ewert DL, Prendergast GC. Bin1 mediates apoptosis by c-Myc in transformed primary cells. Cancer Res. 2001;61(7):3151\u20136.","journal-title":"Cancer Res"},{"issue":"1","key":"384_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/ng0996-69","volume":"14","author":"D Sakamuro","year":"1996","unstructured":"Sakamuro D, Elliott KJ, Wechsler-Reya R, Prendergast GC. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat Genet. 1996;14(1):69\u201377.","journal-title":"Nat Genet"},{"issue":"24","key":"384_CR15","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1038\/sj.onc.1202670","volume":"18","author":"K Elliott","year":"1999","unstructured":"Elliott K, Sakamuro D, Basu A, Du W, Wunner W, Staller P, et al. Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms. Oncogene. 1999;18(24):3564\u201373.","journal-title":"Oncogene"},{"issue":"41","key":"384_CR16","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1038\/sj.onc.1203681","volume":"19","author":"K Elliott","year":"2000","unstructured":"Elliott K, Ge K, Du W, Prendergast GC. The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program. Oncogene. 2000;19(41):4669\u201384.","journal-title":"Oncogene"},{"issue":"3","key":"384_CR17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/(SICI)1097-4644(19990901)74:3<313::AID-JCB1>3.0.CO;2-Z","volume":"74","author":"U Galderisi","year":"1999","unstructured":"Galderisi U, Di Bernardo G, Cipollaro M, Jori FP, Piegari E, Cascino A, et al. Induction of apoptosis and differentiation in neuroblastoma and astrocytoma cells by the overexpression of Bin1, a novel myc interacting protein. J Cell Biochem. 1999;74(3):313\u201322.","journal-title":"J Cell Biochem"},{"issue":"17","key":"384_CR18","doi-asserted-by":"publisher","first-page":"9689","DOI":"10.1073\/pnas.96.17.9689","volume":"96","author":"K Ge","year":"1999","unstructured":"Ge K, DuHadaway J, Du W, Herlyn M, Rodeck U, Prendergast GC. Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc Natl Acad Sci U S A. 1999;96(17):9689\u201394.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"384_CR19","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/(SICI)1097-0215(20000201)85:3<376::AID-IJC14>3.0.CO;2-1","volume":"85","author":"K Ge","year":"2000","unstructured":"Ge K, Duhadaway J, Sakamuro D, Wechsler-Reya R, Reynolds C, Prendergast GC. Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. Int J Cancer. 2000;85(3):376\u201383.","journal-title":"Int J Cancer"},{"issue":"2","key":"384_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/(SICI)1097-0215(20000415)86:2<155::AID-IJC2>3.0.CO;2-M","volume":"86","author":"K Ge","year":"2000","unstructured":"Ge K, Minhas F, Duhadaway J, Mao NC, Wilson D, Buccafusca R, et al. Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. Int J Cancer. 2000;86(2):155\u201361.","journal-title":"Int J Cancer"},{"issue":"2","key":"384_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1479-7364-2-2-138","volume":"2","author":"V Vasiliou","year":"2005","unstructured":"Vasiliou V, Nebert DW. Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Hum Genomics. 2005;2(2):138\u201343.","journal-title":"Hum Genomics"},{"issue":"11","key":"384_CR22","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrn963","volume":"3","author":"M Maden","year":"2002","unstructured":"Maden M. Retinoid signalling in the development of the central nervous system. Nat Rev Neurosci. 2002;3(11):843\u201353.","journal-title":"Nat Rev Neurosci"},{"issue":"15","key":"384_CR23","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1182\/blood-2011-06-364182","volume":"119","author":"JM Gerber","year":"2012","unstructured":"Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Morsberger L, et al. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood. 2012;119(15):3571\u20137.","journal-title":"Blood"},{"issue":"5","key":"384_CR24","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","volume":"1","author":"C Ginestier","year":"2007","unstructured":"Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555\u201367.","journal-title":"Cell Stem Cell"},{"issue":"16","key":"384_CR25","doi-asserted-by":"publisher","first-page":"9118","DOI":"10.1073\/pnas.96.16.9118","volume":"96","author":"RW Storms","year":"1999","unstructured":"Storms RW, Trujillo AP, Springer JB, Shah L, Colvin OM, Ludeman SM, et al. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci U S A. 1999;96(16):9118\u201323.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"384_CR26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00432-022-04524-x","volume":"149","author":"S Wan","year":"2023","unstructured":"Wan S, Cao J, Chen S, Yang J, Wang H, Wang C, et al. Construction of noninvasive prognostic model of bladder cancer patients based on urine proteomics and screening of natural compounds. J Cancer Res Clin Oncol. 2023;149(1):281\u201396.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"384_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-022-01312-5","volume":"15","author":"W Zhang","year":"2022","unstructured":"Zhang W, He X, Yin H, Cao W, Lin T, Chen W, et al. Allosteric activation of the metabolic enzyme GPD1 inhibits bladder cancer growth via the lysoPC-PAFR-TRPV2 axis. J Hematol Oncol. 2022;15(1):93.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"384_CR28","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.cell.2018.03.034","volume":"173","author":"TM Malta","year":"2018","unstructured":"Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al. Machine learning identifies stemness features Associated with Oncogenic Dedifferentiation. Cell. 2018;173(2):338\u2013e354315.","journal-title":"Cell"},{"key":"384_CR29","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.","journal-title":"BMC Bioinformatics"},{"issue":"19","key":"384_CR30","first-page":"1980","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder Cancer: Rev JAMA. 2020;324(19):1980\u201391.","journal-title":"Bladder Cancer: Rev JAMA"},{"key":"384_CR31","doi-asserted-by":"crossref","unstructured":"Flores Monar GV, Reynolds T, Gordon M, Moon D, Moon C. Molecular markers for bladder Cancer screening: an insight into bladder Cancer and FDA-Approved biomarkers. Int J Mol Sci 2023, 24(18).","DOI":"10.3390\/ijms241814374"},{"issue":"10061","key":"384_CR32","first-page":"2796","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstrom PU, Choi W, et al. Bladder cancer Lancet. 2016;388(10061):2796\u2013810.","journal-title":"Bladder cancer Lancet"},{"key":"384_CR33","unstructured":"Springer SU, Chen CH, Rodriguez Pena MDC, Li L, Douville C, Wang Y et al. Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. Elife 2018, 7."},{"issue":"1","key":"384_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskjot","year":"2023","unstructured":"Dyrskjot L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, et al. Bladder cancer. Nat Rev Dis Primers. 2023;9(1):58.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"384_CR35","first-page":"3345","volume":"9","author":"T Tajiri","year":"2003","unstructured":"Tajiri T, Liu X, Thompson PM, Tanaka S, Suita S, Zhao H, et al. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clin Cancer Res. 2003;9(9):3345\u201355.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"384_CR36","doi-asserted-by":"publisher","first-page":"7605","DOI":"10.1158\/0008-5472.CAN-07-1100","volume":"67","author":"MY Chang","year":"2007","unstructured":"Chang MY, Boulden J, Katz JB, Wang L, Meyer TJ, Soler AP, et al. Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res. 2007;67(16):7605\u201312.","journal-title":"Cancer Res"},{"issue":"1","key":"384_CR37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/0008-5472.CAN-06-2742","volume":"67","author":"MY Chang","year":"2007","unstructured":"Chang MY, Boulden J, Sutanto-Ward E, Duhadaway JB, Soler AP, Muller AJ, et al. Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Res. 2007;67(1):100\u20137.","journal-title":"Cancer Res"},{"key":"384_CR38","doi-asserted-by":"publisher","first-page":"619517","DOI":"10.3389\/fonc.2021.619517","volume":"11","author":"MX Li","year":"2021","unstructured":"Li MX, Wang HY, Yuan CH, Ma ZL, Jiang B, Li L, et al. Establishment of a macrophage phenotypic switch related prognostic signature in patients with pancreatic Cancer. Front Oncol. 2021;11:619517.","journal-title":"Front Oncol"},{"key":"384_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.lungcan.2019.02.005","volume":"130","author":"T Ahmadzada","year":"2019","unstructured":"Ahmadzada T, Lee K, Clarke C, Cooper WA, Linton A, McCaughan B, et al. High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes. Lung Cancer. 2019;130:35\u201341.","journal-title":"Lung Cancer"},{"issue":"6","key":"384_CR40","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/leu.2015.9","volume":"29","author":"S Esmailzadeh","year":"2015","unstructured":"Esmailzadeh S, Huang Y, Su MW, Zhou Y, Jiang X. BIN1 tumor suppressor regulates Fas\/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma. Leukemia. 2015;29(6):1402\u201313.","journal-title":"Leukemia"},{"issue":"5","key":"384_CR41","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00109-014-1138-1","volume":"92","author":"I Prokic","year":"2014","unstructured":"Prokic I, Cowling BS, Laporte J. Amphiphysin 2 (BIN1) in physiology and diseases. J Mol Med (Berl). 2014;92(5):453\u201363.","journal-title":"J Mol Med (Berl)"},{"issue":"12","key":"384_CR42","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/cdd.2009.98","volume":"16","author":"EK Cassimere","year":"2009","unstructured":"Cassimere EK, Pyndiah S, Sakamuro D. The c-MYC-interacting proapoptotic tumor suppressor BIN1 is a transcriptional target for E2F1 in response to DNA damage. Cell Death Differ. 2009;16(12):1641\u201353.","journal-title":"Cell Death Differ"},{"issue":"2","key":"384_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1248\/yakushi.16-00229-1","volume":"137","author":"T Mashima","year":"2017","unstructured":"Mashima T. [Cancer Stem cells (CSCs) as a rational therapeutic Cancer target, and screening for CSC-targeting drugs]. Yakugaku Zasshi. 2017;137(2):129\u201332.","journal-title":"Yakugaku Zasshi"},{"key":"384_CR44","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3389\/fphar.2020.00904","volume":"11","author":"S Tanabe","year":"2020","unstructured":"Tanabe S, Quader S, Cabral H, Ono R. Interplay of EMT and CSC in Cancer and the potential therapeutic strategies. Front Pharmacol. 2020;11:904.","journal-title":"Front Pharmacol"},{"issue":"7","key":"384_CR45","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3109\/07357907.2015.1034869","volume":"33","author":"R Roudi","year":"2015","unstructured":"Roudi R, Korourian A, Shariftabrizi A, Madjd Z. Differential expression of Cancer Stem cell markers ALDH1 and CD133 in various Lung Cancer subtypes. Cancer Invest. 2015;33(7):294\u2013302.","journal-title":"Cancer Invest"},{"issue":"1","key":"384_CR46","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.5301\/jbm.5000165","volume":"31","author":"E Erfani","year":"2016","unstructured":"Erfani E, Roudi R, Rakhshan A, Sabet MN, Shariftabrizi A, Madjd Z. Comparative expression analysis of putative cancer stem cell markers CD44 and ALDH1A1 in various skin cancer subtypes. Int J Biol Markers. 2016;31(1):e53\u201361.","journal-title":"Int J Biol Markers"},{"issue":"5415","key":"384_CR47","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.284.5415.770","volume":"284","author":"S Artavanis-Tsakonas","year":"1999","unstructured":"Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284(5415):770\u20136.","journal-title":"Science"},{"issue":"10","key":"384_CR48","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/nm.3678","volume":"20","author":"T Rampias","year":"2014","unstructured":"Rampias T, Vgenopoulou P, Avgeris M, Polyzos A, Stravodimos K, Valavanis C, et al. A new tumor suppressor role for the notch pathway in bladder cancer. Nat Med. 2014;20(10):1199\u2013205.","journal-title":"Nat Med"},{"issue":"12","key":"384_CR49","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1158\/1078-0432.CCR-15-2360","volume":"22","author":"T Hayashi","year":"2016","unstructured":"Hayashi T, Gust KM, Wyatt AW, Goriki A, Jager W, Awrey S, et al. Not all NOTCH is created equal: the oncogenic role of NOTCH2 in bladder Cancer and its implications for targeted therapy. Clin Cancer Res. 2016;22(12):2981\u201392.","journal-title":"Clin Cancer Res"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00384-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-025-00384-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00384-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:37:25Z","timestamp":1740746245000},"score":1,"resource":{"primary":{"URL":"https:\/\/hereditasjournal.biomedcentral.com\/articles\/10.1186\/s41065-025-00384-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["384"],"URL":"https:\/\/doi.org\/10.1186\/s41065-025-00384-w","relation":{},"ISSN":["1601-5223"],"issn-type":[{"value":"1601-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent to participate Ethical approval was obtained from the Institutional Review Board and Human Ethics Committee of the The Second Hospital of Lanzhou University for this study. All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed. Animal research was approved by the Animal Research Committee of Lanzhou University (No, 2024\u00a0A-398).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}